肾脏葡萄糖处理生理学:SGLT1、SGLT2与GLUT2
综述总结肾脏近端小管经SGLT1、SGLT2和GLUT2重吸收葡萄糖的生理机制,指出小鼠和人类敲除这些转运体或静脉注射根皮苷均导致滤过葡萄糖随尿排出,相关发现推动了SGLT2抑制剂格列氟嗪类治疗2型糖尿病的开发。
要点
- 血浆葡萄糖维持在4-10 mmol/l窄范围内,肾脏防止葡萄糖从尿中丢失。
- 近端小管顶膜SGLT1和SGLT2及基底膜GLUT2负责滤过葡萄糖重吸收。
- 小鼠和人类敲除这些转运体或静脉注射根皮苷导致滤过葡萄糖排泄。
核心结论
- 肾脏通过SGLT1、SGLT2和GLUT2重吸收葡萄糖以维持血糖稳态;相关生理发现为SGLT2抑制剂治疗2型糖尿病提供了背景。
研究设计与样本
- 综述总结肾脏葡萄糖处理生理学及SGLT2抑制剂开发背景,引用小鼠和人类转运体敲除及根皮苷静脉注射研究。
主要发现
- 小鼠和人类敲除SGLT1、SGLT2或GLUT2转运体导致滤过葡萄糖随尿排出。
- 人类静脉注射植物糖苷根皮苷也导致全部滤过葡萄糖负荷排出。
- 动物模型中根皮苷逆转糖尿病症状,刺激了SGLT2抑制剂格列氟嗪类的开发与成功引入。
关键数值与推荐
- 血浆葡萄糖浓度维持在4-10 mmol/l窄范围内,主要确保大脑燃料供应。
- 近端小管顶膜SGLT1和SGLT2及基底膜GLUT2负责葡萄糖重吸收。
临床怎么用
- 综述提供SGLT2抑制剂用于2型糖尿病治疗的肾脏葡萄糖处理生理学背景。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The concentration of glucose in plasma is held within narrow limits (4-10 mmol/l), primarily to ensure fuel supply to the brain. Kidneys play a role in glucose homeostasis in the body by ensuring that glucose is not lost in the urine. Three membrane proteins are responsible for glucose reabsorption from the glomerular filtrate in the proximal tubule: sodium-glucose cotransporters SGLT1 and SGLT2, in the apical membrane, and GLUT2, a uniporter in the basolateral membrane. 'Knockout' of these transporters in mice and men results in the excretion of filtered glucose in the urine. In humans, intravenous injection of the plant glucoside phlorizin also results in excretion of the full filtered glucose load. This outcome and the finding that, in an animal model, phlorizin reversed the symptoms of diabetes, has stimulated the development and successful introduction of SGLT2 inhibitors, gliflozins, in the treatment of type 2 diabetes mellitus. Here we summarise the current state of our knowledge about the physiology of renal glucose handling and provide background to the development of SGLT2 inhibitors for type 2 diabetes treatment.
引用
- Ghezzi C, Loo DDF, Wright EM, et al. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018. PMID: 30132032. doi:10.1007/s00125-018-4656-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。